Esophageal squamous cell carcinoma (ESCC) is a lethal malignancy. However, there are few useful markers for diagnosis and treatment. Glutathione S-transferase Pi 1 (GSTP1) has been reported as a predictor of malignancy or anticancer drug resistance in some cancers. We investigated the association of GSTP1 expression with the malignancy or drug resistance in ESCC cell lines and clinical tissue samples.
Proliferation and apoptosis assays regarding GSTP1 expression were examined in ESCC cell lines. Proliferation of GSTP1 knockdown cells was significantly decreased (P < .01), and the frequency of early apoptosis was increased (P < .05). Invasion capacity of GSTP1 knockdown cells was slightly decreased in transwell assay. These results suggest that GSTP1 plays an important role in malignant potential. To examine the effects of GSTP1 on drug resistance, chemosensitivity assay and apoptosis assay under cisplatin exposure were carried out. Viability of GSTP1 knockdown cells treated with cisplatin was lower than that of control cells (P < .01). Moreover, the frequency of early and late apoptosis in GSTP1 knockdown cells was markedly increased over that of control cells by cisplatin exposure (P < .01). In immunohistochemistry assay of resected tissue samples, GSTP1 expression was significantly associated with clinical downstaging (P = .04) in 72 ESCC patients with neoadjuvant chemotherapy. Furthermore, there was a significant association between GSTP1 expression in resected tissue and biopsy samples in 34 ESCC patients without neoadjuvant chemotherapy (P = .02). In summary, GSTP1 was related to malignant potential and may be a predictive marker of drug resistance in ESCC patients.
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| INTRODUC TI ON
Esophageal cancer (EC) is one of the most common and aggressive malignancies. Worldwide, there are about 400 000 newly diagnosed patients and about 300 000 related deaths each year.
1 EC has two main subtypes, ESCC and esophageal adenocarcinoma. ESCC accounts for approximately 90% of EC patients in East Asia. 2 Despite recent advances in diagnosis and treatment, the prognosis and mortality rate of patients with EC are generally poor. 1, 2 With regard to treatment for locally advanced ESCC, surgical resection in combination with chemo-and/or radiation therapy is believed to obtain a better prognosis. However, some patients treated with neoadjuvant chemotherapy do not show a significant response to those treatments. 3 Moreover, there is no useful marker for responses to the chemotherapy.
Glutathione S-transferase Pi 1 is a member of the GST family, a superfamily of dimeric phase-II metabolic enzymes for the cellular defense system, and plays an important role in detoxification. 
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In a previous study, we showed that high GSTP1 expression of the resected specimen was one of the independent predictors of a poor prognosis in ESCC patients who had undergone radical esophagectomy. Five-year overall survival rate of patients with high GSTP1 expression was significantly lower than those with low GSTP1 expression in subgroup analysis among patients who underwent postoperative adjuvant chemotherapy. 19 In the present study, we investigated the significance of GSTP1 expression in malignant potential and sensitivity to chemotherapy using ESCC cell lines, and immunohistochemistry of ESCC patients who underwent neoadjuvant chemotherapy was examined in resected tissues. In addition, immunohistochemistry of paired biopsy and resected tissue samples obtained from ESCC patients without neoadjuvant chemotherapy was also examined.
| MATERIAL S AND ME THODS

| Cells and cell culture
Human ESCC cell line TE13 was obtained from Riken Cell Bank (Tsukuba, Japan). The human ESCC cell line KYSE170 was obtained from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan). Cells were passaged and stored at −80°C in our laboratory for fewer than 6 months after receipt. All experiments were carried out within eight passages of resuscitation. The cells were maintained in a culture medium consisting of RPMI-1640 (Life 
| Western blotting
Cells were lysed by M-PER Mammalian Protein Extraction Reagent (ThermoFisher) and centrifuged at 20 600 g for 10 minutes. The supernatant was collected, and protein concentrations were determined using a Protein Assay Rapid Kit Wako II (Wako, Tokyo, Japan).
Cell lysate (20 ng) was separated on a 12% SDS-PAGE gel, transferred onto PVDF membranes (GE Healthcare, Piscataway, NJ, USA)
and immunoblotted with the indicated antibodies. Antibody against GSTP1 was purchased from Sigma-Aldrich (St Louis, MO, USA). An ECL Plus Western Blotting Detection System was used to detect proteins (GE Healthcare). WST-8 and apoptosis assay were used to evaluate sensitivity to CDDP. IC 50 of CDDP in KYSE170 and TE13 cells is shown in Figure S1 . 
| Small interfering RNA transfection
| Cell proliferation and transwell assay
| Cell cycle assay using FACS analysis
| Chemosensitivity assay
| Apoptosis assay using FACS analysis
| Patients and tumor samples
| Immunohistochemistry assay
Formalin-fixed paraffin-embedded sections of resected tissue and biopsy samples in ESCC patients were subjected to immunostaining with a rabbit monoclonal antibody against GSTP1. Tissue sections 19 GSTP1 expression was divided into two groups: tissues of grade 1 were stained less than 90%, and tissues of grade 2 were stained over 90% of the cancer area as described in the previous study. 
| Statistical analysis
For mRNA analysis, expression levels of GSTP1 in cell lines were compared with the ⊿⊿Ct method. Mann-Whitney U test and the t test for unpaired data were used for transwell invasion and migration assays, cell cycle analysis and apoptotic cell analysis.
Chi-squared test was used to estimate relationships between expression of GSTP1 levels and clinicopathological factors. All data were analyzed in JMP software v11. Reproducibility of the grading classification of the immunochemistry assay was tested by obtaining κ-scores. 19 For the survival rate analysis, differences among the groups were analyzed with the log-rank test or the Wilcoxon test. P-value <.05 was considered statistically significant. Data are reported as mean ± SD.
| RE SULTS
| Effects of GSTP1 expression in ESCC cell lines
Glutathione S-transferase Pi 1 expression in ESCC cell lines was upregulated compared with the normal fibroblast cell line, especially in KYSE170 and TE13, as described in the previous study.
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RNA expression of GSTP1 was reduced by siRNA specific to GSTP1 (si#1: HSS104545, si#2: HSS104546) compared with a negative control (Stealth siRNA: #12935112) in KYSE170 and TE13 cells ( Figure 1A ). Protein expression of GSTP1 was obviously reduced by si#2, but not as much by si#1 ( Figure 1B ). Given these results, si#2 was appropriate for the knockdown of GSTP1 expression.
A WST-8 assay was carried out to evaluate the effects of GSTP1 expression on proliferation in KYSE170 and TE13 cells. Proliferation was suppressed by the reduction of GSTP1 expression ( Figure 1C ).
Moreover, cleaved caspase-3 and PARP protein expression, which are activated during apoptotic induction, were elevated in western blot analysis ( Figure 1D) .
Transwell assays were then used to investigate the effects of GSTP1 on cell invasion and migration. As shown in Figure 2 , invasion capacities of KYSE170 and TE13 cells were decreased by the reduction of GSTP1 expression. However, there was no significant difference in migration capacities regarding GSTP1 expression.
| Significance of GSTP1 expression on the cell cycle and apoptosis
Significance of GSTP1 expression on the cell cycle profile and apoptosis induction were examined using FACS. In the cell cycle analysis, subG0/ G1 phase was relatively increased by the reduction of GSTP1 expression in KYSE170 and TE13 cells ( Figure 3A) . Similarly, early apoptosis was increased in both cell lines, especially in TE13 ( Figure 3B ).
| Drug resistance against CDDP by GSTP1 expression
As shown in Figure 4A , sensitivity to a high dose of CDDP was increased by the reduction of GSTP1 expression in both cell lines.
Furthermore, early and late apoptosis by CDDP (4 μmol/L) treatment was markedly promoted by the reduction of GSTP1 expression ( Figure 4B ). These results indicate that GSTP1 expression associates with drug resistance against CDDP.
F I G U R E 1 Knockdown of glutathione S-transferase Pi 1 (GSTP1) expression and the proliferation assay. A, Downregulation of GSTP1
expression by transfection of siGSTP1 was confirmed in KYSE170 and TE13 cell lines using PCR. B, GSTP1 protein expression was detected by western blotting. KYSE170 and TE13 cell lines were transfected with siGSTP1 and siControl. C, Proliferation was decreased by transfection with siGSTP1 #2 in KYSE170 and TE13 cell lines. Error bars indicate SD. *P < .05; **P < .01; n = 3. D, Results of western blotting analysis for GSTP1, cleaved caspase 3, cleaved cleaved-poly (ADP-ribosyl) polymerase (PARP) and β-actin protein expression are shown.
Proteins of KYSE170 and TE13 cell lines were collected at 72 h after transfection with siGSTP1 #2 and the control
| Immunohistochemistry of GSTP1 in ESCC tissue and biopsy samples
Immunohistochemistry was carried out for GSTP1 protein expression in the resected tissue samples of ESCC patients treated with neoadjuvant chemotherapy. GSTP1 expression was mainly detected in the nuclei and cytoplasm of cancer cells, and also in the superficial layer of the normal esophageal epithelium (Figure S2a-d) . The patients were divided into two groups, grade 1 and grade 2, on the basis of the judgement criteria of the previous study described in Materials and Methods. 19 Twenty-three patients (31.9%) of all 72 patients were divided into grade 1, and 49 patients (68.1%) were divided into grade 2 (Table 1) .
Relationships between GSTP1 grade and clinicopathological factors are shown in Table 1 were also marginally related to GSTP1 grade.
Immunohistochemistry for GSTP1 protein expression in the biopsy samples before operation and resected cancerous tissue samples was also carried out using 34 paired samples obtained from patients without neoadjuvant chemotherapy. GSTP1 expression level of biopsy samples was significantly correlated with that of tissue samples (P = .02, Table 2 ). Clinicopathological factors and GSTP1 grade in the 34 patients are shown in Table S1 .
| D ISCUSS I ON
On the basis of the results of the JCOG 9907 study, 22 neoadjuvant chemotherapy followed by conventional surgery is one of the standardized therapeutic approaches for localized advanced ESCC in Japan. However, the prognosis and mortality rate of advanced ESCC patients remain poor. In addition, there are few useful markers widely accepted as a predictor of prognosis or chemotherapeutic efficacy. Regarding chemotherapy, some patients do not respond to the treatment and cannot undergo surgery because of disease progression or adverse events. 3, 22, 23 Some markers for chemotherapy sensitivity, such as caveolin-1 and receptor interactive protein kinase 3, have been reported in ESCC, 24, 25 but no useful marker is clinically accepted.
In the previous study, we reported that high GSTP1 expression was substantially related not only to poor prognosis but also to sensitivity to postoperative adjuvant chemotherapy in clinical analysis. 19 Therefore, in the present study, we hypothesized that GSTP1
promotes tumor progression or drug resistance and examined the role of GSTP1 in ESCC cell lines.
Glutathione S-transferases are well-known enzymes for catalytic activities to eliminate toxic substances and oxidative stress, binding of non-substrate ligands such as thyroid hormone, and protein-protein interactions. In addition to such detoxifications, GSTP1 was also reported to be involved in cell survival and in the death signaling pathway through MAPK including JNK, p38 MAPK, and ERK, 26, 27 which might contribute to the protection of tumor cells. [28] [29] [30] Interestingly, the relationship between GSTP1 expression and tumor progression has been reported in cervical cancer, 31 breast cancer, 32 and other types of cancers. 33 Some reports, including our previous study, described that GSTP1 promotes tumor progression in ESCC patients. 19, 34 In the present study, proliferation was markedly inhibited by reduction of GSTP1 expression, and apoptosis was induced. These results were also confirmed by upregulation of apoptosis-related protein expression, such as cleaved caspase-3 or PARP. In non-stressed cells, GSTP1 binds to JNK or TRAF2 to maintain low JNK activity. 26, 27 Therefore, higher expression of GSTP1 in tumor cells may prevent tumor apoptosis and protect tumor cells from oxidative stress.
Relationships between GSTP1 expression and cell survival have been described in many reports. However, the impact of GSTP1 on tumor invasion and migration has not been sufficiently researched.
Lin et al described that GSTP1 played a critical role in microRNA (miR)-133b-mediated tumor migration and was substantially related to MMP expression, although the effects on tumor invasion
were not investigated. 7 In the present study, invasion capacity of ESCC cell lines was decreased by knockdown of GSTP1 expression, whereas migration capacity was not. Although the difference in GSTP1 effects on invasion and migration capacity remains unclear, GSTP1-related MMP may promote tumor progression.
Recently, the significance of GSTP1 for evaluating sensitivity to anticancer drugs such as CDDP, Univariate analysis
Pvalue
Gender Lymph node metastasis 36 In the chemosensitivity assay, viability of GSTP1 knockdown cells was significantly decreased by CDDP treatment, although proliferation was also decreased by GSTP1 knockdown.
Moreover, in the apoptosis assay, early and late apoptosis rates by CDDP treatment were strongly increased in GSTP1 knockdown cells. However, these results were not obtained with 5-FU treatment. Therefore, it is considered that GSTP1 has an important role for drug resistance against CDDP in ESCC cell lines.
Glutathione S-transferase Pi 1 prevents JNK activity by forming a complex with JNK in non-stressed cells, while dissociation of the complex occurs under oxidative stress and JNK activity is increased. 26 Furthermore, GSTP1 was reported to modulate ERK1/2 rather than JNK under oxidative stress such as CDDP treatment. Miyake et al also reported the value of GSTP1 expression in biopsy samples of breast cancer patients as a biomarker for response to neoadjuvant chemotherapy. 38 In the present study, there was a significant correlation between GSTP1 expression in biopsy and resected tissue samples obtained from patients without neoadjuvant chemotherapy (P = 0.2, Table 2 ). This may show that GSTP1 expression level of biopsy samples can be a useful marker to predict tumor progression and chemosensitivity, although the number of analyzable cases was small and a larger study in biopsy samples is needed. Furthermore, considering tumor heterogeneity, more sections at several intervals of cancerous tissue or biopsy samples should be assessed to provide more accurate information on GSTP1 expression.
Second, we simply evaluated the expression level of GSTP1 in cell lines and tissue or biopsy samples, and the molecular biology or genetic alterations of GSTP1 for tumor progression was not sufficiently researched. Some reports noted that GSTP1
is associated with the MAPK pathway, which results in a poor prognosis. 26, 27 Moreover, the association of GSTP1 polymorphism and survival in esophageal cancer was also reported.
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In this regard, some factors related to analyses of the molecular pathway including JNK and ERK, or polymorphism may be necessary.
In conclusion, GSTP1 plays an important role in malignant potential and drug resistance in vitro and can be a novel surrogate predictor of drug resistance in ESCC. Further research of GSTP1 using a larger number of biopsy samples should be carried out to provide more effective clinical application in ESCC patients.
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